Details
Stereochemistry | ACHIRAL |
Molecular Formula | C8H11N2O3.Na |
Molecular Weight | 206.1743 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[Na+].CCC1(CC)C(=O)NC(=O)[N-]C1=O
InChI
InChIKey=RGHFKWPGWBFQLN-UHFFFAOYSA-M
InChI=1S/C8H12N2O3.Na/c1-3-8(4-2)5(11)9-7(13)10-6(8)12;/h3-4H2,1-2H3,(H2,9,10,11,12,13);/q;+1/p-1
Molecular Formula | C8H12N2O3 |
Molecular Weight | 184.1925 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | Na |
Molecular Weight | 22.98976928 |
Charge | 1 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Barbital, the one of the series of barbiturates, has hypnotic, sedative, and anticonvulsant properties and used under the trade name Veronal. It calmed manic patients and helped melancholic patients to sleep and was an effective inducer of sleep in insomniacs, but at the same time compound could induced dependence. It was substituted by the butyl analog, butobarbital, which was three times stronger and its period of action was much shorter due to its lipophilicity. Barbital is a ligand of GABA-receptor complex and in addition, it could have another target, a creatine kinase.
CNS Activity
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: GABA receptor Sources: https://www.ncbi.nlm.nih.gov/pubmed/1654164 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Veronal Approved UseUnknown |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
300 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/957863/ |
200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered: |
BARBITAL plasma | Rattus norvegicus population: HEALTHY age: ADULT sex: MALE food status: FASTED |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
3860 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/957863/ |
200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered: |
BARBITAL plasma | Rattus norvegicus population: HEALTHY age: ADULT sex: MALE food status: FASTED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
6 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/957863/ |
200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered: |
BARBITAL plasma | Rattus norvegicus population: HEALTHY age: ADULT sex: MALE food status: FASTED |
Doses
Dose | Population | Adverse events |
---|---|---|
5 g 1 times / day single, oral Studied dose Dose: 5 g, 1 times / day Route: oral Route: single Dose: 5 g, 1 times / day Sources: |
unhealthy, 19 years |
Other AEs: Coma... |
250 mg 3 times / day multiple, oral Studied dose Dose: 250 mg, 3 times / day Route: oral Route: multiple Dose: 250 mg, 3 times / day Sources: |
unhealthy, median age 44 years Health Status: unhealthy Age Group: median age 44 years Sex: M+F Sources: |
Other AEs: Dizziness, Drug intoxication... Other AEs: Dizziness Sources: Drug intoxication Euphoric Tiredness |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Coma | 5 g 1 times / day single, oral Studied dose Dose: 5 g, 1 times / day Route: oral Route: single Dose: 5 g, 1 times / day Sources: |
unhealthy, 19 years |
|
Dizziness | 250 mg 3 times / day multiple, oral Studied dose Dose: 250 mg, 3 times / day Route: oral Route: multiple Dose: 250 mg, 3 times / day Sources: |
unhealthy, median age 44 years Health Status: unhealthy Age Group: median age 44 years Sex: M+F Sources: |
|
Drug intoxication | 250 mg 3 times / day multiple, oral Studied dose Dose: 250 mg, 3 times / day Route: oral Route: multiple Dose: 250 mg, 3 times / day Sources: |
unhealthy, median age 44 years Health Status: unhealthy Age Group: median age 44 years Sex: M+F Sources: |
|
Euphoric | 250 mg 3 times / day multiple, oral Studied dose Dose: 250 mg, 3 times / day Route: oral Route: multiple Dose: 250 mg, 3 times / day Sources: |
unhealthy, median age 44 years Health Status: unhealthy Age Group: median age 44 years Sex: M+F Sources: |
|
Tiredness | 250 mg 3 times / day multiple, oral Studied dose Dose: 250 mg, 3 times / day Route: oral Route: multiple Dose: 250 mg, 3 times / day Sources: |
unhealthy, median age 44 years Health Status: unhealthy Age Group: median age 44 years Sex: M+F Sources: |
PubMed
Title | Date | PubMed |
---|---|---|
Modifying potential of thirty-one chemicals on the short-term development of gamma-glutamyl transpeptidase-positive foci in diethylnitrosamine-initiated rat liver. | 1984 Oct |
|
Comparative tumor-promoting activities of phenobarbital, amobarbital, barbital sodium, and barbituric acid on livers and other organs of male F344/NCr rats following initiation with N-nitrosodiethylamine. | 1985 Feb |
|
Drugs as allergens: the molecular basis of IgE binding to thiopentone. | 1987 |
|
The chronic hepatic or renal toxicity of di(2-ethylhexyl) phthalate, acetaminophen, sodium barbital, and phenobarbital in male B6C3F1 mice: autoradiographic, immunohistochemical, and biochemical evidence for levels of DNA synthesis not associated with carcinogenesis or tumor promotion. | 1988 Dec |
|
Effects of sodium salts of phenobarbital and barbital on development of bladder tumors in male F344/NCr rats pretreated with either N-[4-(5-nitro-2-furyl)-2-thiazolyl]formamide or N-nitrosobutyl-4-hydroxybutylamine. | 1989 Apr |
|
Promotion by sodium barbital of renal cortical and transitional cell tumors, but not intestinal tumors, in F344 rats given methyl(acetoxymethyl)nitrosamine, and lack of effect of phenobarbital, amobarbital, or barbituric acid on development of either renal or intestinal tumors. | 1989 Jan |
|
Induction of CYP2B1 mediated pentoxyresorufin O-dealkylase activity in different species, sex and tissue by prototype 2B1-inducers. | 1995 Mar 30 |
|
The effects of some porphyrinogenic drugs on the brain cholinergic system. | 2002 Feb |
|
Immunoelectrophoresis of red blood cells performed on microcapillary chips. | 2002 Jul |
|
Molecular "chaperones" guide the spontaneous formation of a 15-component hydrogen-bonded assembly. | 2002 Jul 3 |
|
Secretion of soluble complement inhibitors factor H and factor H-like protein (FHL-1) by ovarian tumour cells. | 2002 Nov 4 |
|
Supramolecular synthons based on N-H...N and C-H...O hydrogen bonds. Crystal engineering of a helical structure with 5,5-diethylbarbituric acid. | 2002 Sep 7 |
|
Isolation and characterization of anticomplementary beta-glucans from the shoots of bamboo Phyllostachys edulis. | 2003 Jan |
|
Complexation of phenolic guests by endo- and exo-hydrogen-bonded receptors. | 2003 Jul 21 |
|
Rational design of the first closed coordination capsule with octahedral outer shape. | 2004 May 3 |
|
The history of barbiturates a century after their clinical introduction. | 2005 Dec |
|
Rescue of heterochromatin organization in Hutchinson-Gilford progeria by drug treatment. | 2005 Nov |
|
Selective self-organization of guest molecules in self-assembled molecular boxes. | 2005 Sep 14 |
|
Statin-induced expression of CD59 on vascular endothelium in hypoxia: a potential mechanism for the anti-inflammatory actions of statins in rheumatoid arthritis. | 2006 |
|
Carbonic anhydrase in Tectona grandis: kinetics, stability, isozyme analysis and relationship with photosynthesis. | 2006 Aug |
|
Proximal visceral endoderm and extraembryonic ectoderm regulate the formation of primordial germ cell precursors. | 2007 Dec 20 |
|
Modulation of the complement system by human beta-defensin 2. | 2007 Jan 10 |
|
The Inactivation of a New Peptidoglycan Hydrolase Pmp23 Leads to Abnormal Septum Formation in Streptococcus pneumoniae. | 2008 |
|
Floridoside extracted from the red alga Mastocarpus stellatus is a potent activator of the classical complement pathway. | 2008 |
|
The Staphylococcus aureus protein Sbi acts as a complement inhibitor and forms a tripartite complex with host complement Factor H and C3b. | 2008 Dec |
|
Surviving mousepox infection requires the complement system. | 2008 Dec |
|
Variability and action mechanism of a family of anticomplement proteins in Ixodes ricinus. | 2008 Jan 2 |
|
Application of two different kinds of sera against the Proteus penneri lipopolysaccharide core region in search of epitopes determining cross-reactions with antibodies. | 2008 Mar-Apr |
|
EspJ of enteropathogenic and enterohaemorrhagic Escherichia coli inhibits opsono-phagocytosis. | 2008 May |
|
Foamy macrophages from tuberculous patients' granulomas constitute a nutrient-rich reservoir for M. tuberculosis persistence. | 2008 Nov |
|
Pharmacological profiles of animal- and nonanimal-derived sulfated polysaccharides--comparison of unfractionated heparin, the semisynthetic glucan sulfate PS3, and the sulfated polysaccharide fraction isolated from Delesseria sanguinea. | 2009 Apr |
|
Biomass production potential of a wastewater alga Chlorella vulgaris ARC 1 under elevated levels of CO₂and temperature. | 2009 Feb |
|
Interpain A, a cysteine proteinase from Prevotella intermedia, inhibits complement by degrading complement factor C3. | 2009 Feb |
|
Complement consumption in children with Plasmodium falciparum malaria. | 2009 Jan 9 |
|
The glyceraldehyde-3-phosphate dehydrogenase and the small GTPase Rab 2 are crucial for Brucella replication. | 2009 Jun |
|
Brain damage in newborn rat model of meningitis by Enterobacter sakazakii: a role for outer membrane protein A. | 2009 Mar |
|
Some patients with NHL possessed immunoreactivity to gliadin and to cow's milk proteins. | 2009 Sep |
|
Role of genetic polymorphisms in factor H and MBL genes in Tunisian patients with immunoglobulin A nephropathy. | 2010 |
|
Recombinant human complement component C2 produced in a human cell line restores the classical complement pathway activity in-vitro: an alternative treatment for C2 deficiency diseases. | 2010 Aug 20 |
|
Annexin-II, DNA, and histones serve as factor H ligands on the surface of apoptotic cells. | 2010 Feb 5 |
|
Determining the reactivity and titre of serum using a haemagglutination assay. | 2010 Jan 29 |
|
The virulence protein SopD2 regulates membrane dynamics of Salmonella-containing vacuoles. | 2010 Jul 15 |
|
Cell membrane modification for rapid display of bi-functional peptides: a novel approach to reduce complement activation. | 2010 Jul 20 |
|
Complement activation mediates cetuximab inhibition of non-small cell lung cancer tumor growth in vivo. | 2010 Jun 7 |
|
Inefficient complement system clearance of Trypanosoma cruzi metacyclic trypomastigotes enables resistant strains to invade eukaryotic cells. | 2010 Mar 16 |
|
Effects of 17beta-oestradiol and norethisterone acetate on sulfonation and sialylation of gonadotrophins in post-menopausal women. | 2010 May |
|
Combination of pneumococcal surface protein A (PspA) with whole cell pertussis vaccine increases protection against pneumococcal challenge in mice. | 2010 May 27 |
|
A recombinant vaccine effectively induces c5a-specific neutralizing antibodies and prevents arthritis. | 2010 Oct 20 |
|
Complement factor H-related proteins CFHR2 and CFHR5 represent novel ligands for the infection-associated CRASP proteins of Borrelia burgdorferi. | 2010 Oct 20 |
|
Modulation of polymorphonuclear neutrophil functions by astrocytes. | 2010 Sep 9 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/21433434
10 g two times per day
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/16609694
It was reported the action of sodium barbital as an inhibitor of rabbit-muscle creatine kinase (CK), which plays a significant role in energy homeostasis in the muscles. The activity of CK underwent a rapid decrease when the concentration of sodium barbital was increased to 8 mmol/L, and the residual activity was about 35% of then active CK. The activity of CK dropped slowly until it was almost 0 when the concentration of sodium barbital was increased to 125 mmol/L. These results indicated that sodium barbital might function as an inhibitor of CK.
Substance Class |
Chemical
Created
by
admin
on
Edited
Wed Apr 02 09:26:12 GMT 2025
by
admin
on
Wed Apr 02 09:26:12 GMT 2025
|
Record UNII |
275L5M93QS
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C67084
Created by
admin on Wed Apr 02 09:26:12 GMT 2025 , Edited by admin on Wed Apr 02 09:26:12 GMT 2025
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
235404
Created by
admin on Wed Apr 02 09:26:12 GMT 2025 , Edited by admin on Wed Apr 02 09:26:12 GMT 2025
|
PRIMARY | RxNorm | ||
|
DTXSID3020128
Created by
admin on Wed Apr 02 09:26:12 GMT 2025 , Edited by admin on Wed Apr 02 09:26:12 GMT 2025
|
PRIMARY | |||
|
m2227
Created by
admin on Wed Apr 02 09:26:12 GMT 2025 , Edited by admin on Wed Apr 02 09:26:12 GMT 2025
|
PRIMARY | Merck Index | ||
|
C77627
Created by
admin on Wed Apr 02 09:26:12 GMT 2025 , Edited by admin on Wed Apr 02 09:26:12 GMT 2025
|
PRIMARY | |||
|
12598274
Created by
admin on Wed Apr 02 09:26:12 GMT 2025 , Edited by admin on Wed Apr 02 09:26:12 GMT 2025
|
PRIMARY | |||
|
205-613-9
Created by
admin on Wed Apr 02 09:26:12 GMT 2025 , Edited by admin on Wed Apr 02 09:26:12 GMT 2025
|
PRIMARY | |||
|
100000088411
Created by
admin on Wed Apr 02 09:26:12 GMT 2025 , Edited by admin on Wed Apr 02 09:26:12 GMT 2025
|
PRIMARY | |||
|
380
Created by
admin on Wed Apr 02 09:26:12 GMT 2025 , Edited by admin on Wed Apr 02 09:26:12 GMT 2025
|
PRIMARY | |||
|
CHEMBL444
Created by
admin on Wed Apr 02 09:26:12 GMT 2025 , Edited by admin on Wed Apr 02 09:26:12 GMT 2025
|
PRIMARY | |||
|
275L5M93QS
Created by
admin on Wed Apr 02 09:26:12 GMT 2025 , Edited by admin on Wed Apr 02 09:26:12 GMT 2025
|
PRIMARY | |||
|
SUB06103MIG
Created by
admin on Wed Apr 02 09:26:12 GMT 2025 , Edited by admin on Wed Apr 02 09:26:12 GMT 2025
|
PRIMARY | |||
|
144-02-5
Created by
admin on Wed Apr 02 09:26:12 GMT 2025 , Edited by admin on Wed Apr 02 09:26:12 GMT 2025
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |